The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
High Frequency and Poor Outcome of Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia in Adults
Open accessAbstract
Purpose: Philadelphia chromosome (Ph) –like acute lymphoblastic leukemia (ALL) is a high-risk subtype of childhood ALL characterized by kinase-activating alterations that are amenable to treatment with tyrosine kinase inhibitors. We sought to define the prevalence and genomic landscape of Ph-like ALL in adults and assess response to conventional chemotherapy. Patients and Methods: The frequency of Ph-like ALL was assessed by gene expression profiling of 798 patients with B-cell ALL age 21 to 86 years. Event-free survival and overall survival were determined for Ph-like ALL versus non–Ph-like ALL patients. Detailed genomic analysis was performed on 180 of 194 patients with Ph-like ALL. Results: Patients with Ph-like ALL accounted for more than 20% of adults with ALL, including 27.9% of young adults (age 21 to 39 years), 20.4% of adults (age 40 to 59 years), and 24.0% of older adults (age 60 to 86 years). Overall, patients with Ph-like ALL had an inferior 5-year event-free survival compared with patients with non–Ph-like ALL (22.5% [95% CI, 14.9% to 29.3%; n = 155] v 49.3% [95% CI, 42.8% to 56.2%; n = 247], respectively; P < .001). We identified kinase-activating alterations in 88% of patients with Ph-like ALL, including CRLF2 rearrangements (51%), ABL class fusions (9.8%), JAK2 or EPOR rearrangements (12.4%), other JAK-STAT sequence mutations (7.2%), other kinase alterations (4.1%), and Ras pathway mutations (3.6%). Eleven new kinase rearrangements were identified, including four involving new kinase or cytokine receptor genes and seven involving new partners for previously identified genes. Conclusion: Ph-like ALL is a highly prevalent subtype of ALL in adults and is associated with poor outcome. The diverse range of kinase-activating alterations in Ph-like ALL has important therapeutic implications. Trials comparing the addition of tyrosine kinase inhibitors to conventional therapy are required to evaluate the clinical utility of these agents in the treatment of Ph-like ALL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Acute Lymphoblastic Leukemia in Children
Hunger, S. P., & Mullighan, C. G. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1400972 · Cited by 2,204
Self-citationDeletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
Mullighan, C. G., Su, X., Zhang, J., Radtke, I., Phillips, L. A. A., Miller, C. B., Ma, J., Liu, W., Cheng, C., Schulman, B. A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808253 · Cited by 1,422
Self-citationTargetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
Roberts, K. G., Li, Y., Payne-Turner, D., Harvey, R. C., Yang, Y.-L., Pei, D., McCastlain, K., Ding, L., Lu, C., Song, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403088 · Cited by 1,377
Self-citationDen Boer, M. L., van Slegtenhorst, M., De Menezes, R. X., Cheok, M. H., Buijs-Gladdines, J. G., Peters, S. T., Van Zutven, L. J., Beverloo, H. B., Van der Spek, P. J., Escherich, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70339-5 · Cited by 930
Fielding, A. K., Richards, S. M., Chopra, R., Lazarus, H. M., Litzow, M. R., Buck, G., Durrant, I. J., Luger, S. M., Marks, D. I., Franklin, I. M., et al. (2007) · Blood · doi:10.1182/blood-2006-05-018192 · Cited by 841
Self-citationGoldstone, A. H., Richards, S. M., Lazarus, H. M., Tallman, M. S., Buck, G., Fielding, A. K., Burnett, A. K., Chopra, R., Wiernik, P. H., Foroni, L., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116582 · Cited by 778
Self-citationMoorman, A. V., Harrison, C. J., Buck, G. A. N., Richards, S. M., Secker-Walker, L. M., Martineau, M., Vance, G. H., Cherry, A. M., Higgins, R. R., Fielding, A. K., et al. (2007) · Blood · doi:10.1182/blood-2006-10-051912 · Cited by 753
Self-citationRoberts, K. G., Morin, R. D., Zhang, J., Hirst, M., Zhao, Y., Su, X., Chen, S.-C., Payne-Turner, D., Churchman, M. L., Harvey, R. C., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.005 · Cited by 714
Self-citationKantarjian, H., Thomas, D., O'Brien, S., Cortes, J., Giles, F., Jeha, S., Bueso‐Ramos, C. E., Pierce, S., Shan, J., Koller, C., et al. (2004) · Cancer · doi:10.1002/cncr.20668 · Cited by 638
Self-citationThomas, D. A. (2004) · Blood · doi:10.1182/blood-2003-08-2958 · Cited by 571
Bassan, R., Spinelli, O., Oldani, E., Intermesoli, T., Tosi, M., Peruta, B., Rossi, G., Borlenghi, E., Pogliani, E. M., Terruzzi, E., et al. (2009) · Blood · doi:10.1182/blood-2008-11-185132 · Cited by 430
Self-citationThomas, D. A., O'Brien, S., Faderl, S., Garcia-Manero, G., Ferrajoli, A., Wierda, W., Ravandi, F., Verstovsek, S., Jorgensen, J. L., Bueso-Ramos, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9456 · Cited by 416
Self-citationMoorman, A. V., Ensor, H. M., Richards, S. M., Chilton, L., Schwab, C., Kinsey, S. E., Vora, A., Mitchell, C. D., & Harrison, C. J. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70066-8 · Cited by 390
Ravandi, F., O'Brien, S., Thomas, D., Faderl, S., Jones, D., Garris, R., Dara, S., Jorgensen, J., Kebriaei, P., Champlin, R., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261586 · Cited by 348
Self-citationIntegrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting
He, J., Abdel-Wahab, O., Nahas, M. K., Wang, K., Rampal, R. K., Intlekofer, A. M., Patel, J., Krivstov, A., Frampton, G. M., Young, L. E., et al. (2016) · Blood · doi:10.1182/blood-2015-08-664649 · Cited by 311
Self-citationGotlib, J., Cools, J., Malone, J. M., Schrier, S. L., Gilliland, D. G., & Coutré, S. E. (2004) · Blood · doi:10.1182/blood-2003-06-1824 · Cited by 290
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Maude, S. L., Tasian, S. K., Vincent, T., Hall, J. W., Sheen, C., Roberts, K. G., Seif, A. E., Barrett, D. M., Chen, I.-M., Collins, J. R., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415448 · Cited by 289
Self-citationMaude, S. L., Dolai, S., Delgado-Martin, C., Vincent, T., Robbins, A., Selvanathan, A., Ryan, T., Hall, J., Wood, A. C., Tasian, S. K., et al. (2015) · Blood · doi:10.1182/blood-2014-06-580480 · Cited by 226
Self-citationWeston, B. W., Hayden, M. A., Roberts, K. G., Bowyer, S., Hsu, J., Fedoriw, G., Rao, K. W., & Mullighan, C. G. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.6770 · Cited by 213
Self-citationLengline, E., Beldjord, K., Dombret, H., Soulier, J., Boissel, N., & Clappier, E. (2013) · Haematologica · doi:10.3324/haematol.2013.095372 · Cited by 172
Storring, J. M., Minden, M. D., Kao, S., Gupta, V. K., Schuh, A. C., Schimmer, A. D., Yee, K. W. L., Kamel‐Reid, S., Chang, H., Lipton, J. H., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07712.x · Cited by 153
Self-citationLiang, J., van Abbema, A., Balázs, M., Barrett, K., Berezhkovsky, L., Blair, W., Chang, C. C., Delarosa, D., DeVoss, J., Driscoll, J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400266t · Cited by 105
Boer, J. M., Koenders, J. E., van der Holt, B., Exalto, C., Sanders, M. A., Cornelissen, J. J., Valk, P. J. M., den Boer, M. L., & Rijneveld, A. W. (2015) · Haematologica · doi:10.3324/haematol.2014.117424 · Cited by 97
TKI dasatinib monotherapy for a patient with Ph‐like ALL bearing ATF7IP/PDGFRB translocation
Kobayashi, K., Miyagawa, N., Mitsui, K., Matsuoka, M., Kojima, Y., Takahashi, H., Otsubo, K., Nagai, J., Ueno, H., Ishibashi, T., et al. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25327 · Cited by 60
BLNK Binds Active H-Ras to Promote B Cell Receptor-mediated Capping and ERK Activation
Imamura, Y., Oda, A., Katahira, T., Bundo, K., Pike, K. A., Ratcliffe, M. J. H., & Kitamura, D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809051200 · Cited by 34
Cited by
Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. D. O., Berti, E., Bhagat, G., Borges, A. M., Boyer, D., Calaminici, M., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01620-2 · Cited by 4,004
Malard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
Genetic Basis of Acute Lymphoblastic Leukemia
Iacobucci, I., & Mullighan, C. G. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7836 · Cited by 556
Self-citationStock, W., Luger, S. M., Advani, A. S., Yin, J., Harvey, R. C., Mullighan, C. G., Willman, C. L., Fulton, N., Laumann, K. M., Malnassy, G., et al. (2019) · Blood · doi:10.1182/blood-2018-10-881961 · Cited by 488
Self-citationPh-like acute lymphoblastic leukemia: a high-risk subtype in adults
Jain, N., Roberts, K. G., Jabbour, E., Patel, K., Eterovic, A. K., Chen, K., Zweidler-McKay, P., Lu, X., Fawcett, G., Wang, S. A., et al. (2017) · Blood · doi:10.1182/blood-2016-07-726588 · Cited by 387
Self-citation
Metadata
- Authors
- Roberts, K. G., Gu, Z., Payne-Turner, D., McCastlain, K., Harvey, R. C., Chen, I.-M., Pei, D., Iacobucci, I., Valentine, M., Pounds, S. B., Shi, L., Li, Y., Zhang, J., Cheng, C., Rambaldi, A., Tosi, M., Spinelli, O., Radich, J. P., Minden, M. D., Rowe, J. M., Luger, S., Litzow, M. R., Tallman, M. S., Wiernik, P. H., Bhatia, R., Aldoss, I., Kohlschmidt, J., Mrózek, K., Marcucci, G., Bloomfield, C. D., Stock, W., Kornblau, S., Kantarjian, H. M., Konopleva, M., Paietta, E., Willman, C. L., & Mullighan, C. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-02-01
- Volume
- 35
- Issue
- 4
- Pages
- 394-401
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2554580516
- Cited by
- 453
- References
- 28
- FWCI
- 41.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.